
High-throughput (HTP) recombinant antibody production is the rapid generation of large numbers of recombinant antibodies. Recombinant antibodies are monoclonal antibodies which can be produced in vitro through synthetic genes and antibody fragments, instead of using hybridomas. Here are a few reasons why speed is important:
Fast HTP recombinant antibody production enables research to take place more quickly and paves the way towards clinical trials. Demand for antibodies has exponentially risen in recent years due to advancements in fields such as immuno-oncology, personalized medicine, and infectious diseases, and speed is essential to meet these growing demands efficiently.
During the lead identification phase of drug discovery, rapid production allows for quick screening of large antibody libraries against targets of interest, leading to the identification of high-affinity antibodies and potential therapeutic candidates. This helps with drug development, optimizing the time required to progress from initial discovery to candidate selection.
Characterization of antibody function can require high quantities of recombinant antibodies to conduct, such as determining binding affinities, epitope mapping, and characterizing antibody-mediated immune responses. Structural studies such as X-ray crystallography and cryo-electron microscopy also require purified antibodies in substantial quantities. The integration of Biointron’s recombinant protein expression service ensures efficient and scalable production, meeting these demands with unmatched quality and speed. Additionally, a mammalian protein expression service further enhances production capabilities, ensuring high-yield and biologically relevant antibody generation.
Biointron’s 2-week HTP recombinant antibody production is unparalled in the antibody production industry while maintaining the highest quality. At Biointron, we are dedicated to accelerating your antibody discovery, optimization, and production needs. Our team of experts can provide customized solutions that meet your specific research needs. Contact us to learn more about our services and how we can help accelerate your research and drug development projects.
VHH half extension mechanisms like Fc fusion, albumin binding, and PEGylation to……
Learn how multivalent and bispecific VHH antibodies are engineered, their advant……
April 2026 activity saw consolidation in the ADC space, continued expansion of n……
Read on for key trends talked about during the conference: Antibody Therapeutics……
Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.
Biointron uses cookies and similar technologies to ensure proper website functionality, understand how visitors use our website, and improve our content and services. Necessary cookies are enabled by default.
By clicking “Accept All”, you agree to the use of all cookies, including analytics and optional cookies that help us understand website usage and improve user experience. By clicking “Reject Non-Essential”, only necessary cookies will be used.
You may manage or change your cookie preferences at any time by clicking “Cookie Settings” at the bottom of the website.
For more information about how we use cookies and process personal data, please review our Privacy Policy.



